Skip to content

Shop
Scholar
Lab Results
Learn
Vote
Forum
About

Search Kodiac

Sign in Sign up Account

Author: kodiac

Boldenone

Plain-language summaryIntrigue 42 / 100

Boldenone is essentially testosterone with an added double bond between carbons 1 and 2. Originally approved in 1949 as a human drug at Ciba (Parenabol, withdrawn) and later developed for veterinary use as Equipoise, the name still associated with it. The 1,2 double bond makes the molecule a poorer substrate for aromatase, so it converts to estrogen at roughly half the rate of testosterone at equivalent doses, the main practical feature distinguishing it. The undecylenate ester gives the injectable formulation a long half-life around 14 days. Schedule III in the US under the AAS Control Act despite never having current human medical approval. Reference low-aromatizing testosterone analog in steroid pharmacology research. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

24/100

Old veterinary AAS with narrow reference-probe utility and stagnant research trajectory

Boldenone is a 75-year-old compound. That’s the core of the story here. Ciba introduced it in 1949 as Parenabol for human use, pulled it, and it found its permanent home as Equipoise in veterinary practice. The research conversation around it has been essentially stagnant for decades; theres no active clinical development program, no IND, no therapeutic application on the horizon. For a library built around the frontier, boldenone is not there.

The mechanism is straightforward: androgen receptor agonism with the 1,2 double bond reducing aromatase substrate quality to roughly half that of testosterone. That’s the single pharmacological hook distinguishing boldenone from plain testosterone, and while it’s a real and measurable difference, it’s not a novel mechanism. It’s a structural variation on one of the most thoroughly studied receptor systems in endocrinology. Single-receptor agonism in a class that has dozens of characterized analogs doesn’t score high on mechanism promise, and boldenone doesn’t earn any points for mechanism elegance beyond that one structural tweak.

Where boldenone has some legitimate research value is as a reference compound. If you’re running in vitro or in vivo androgen biology work and you want to separate androgenic effects from estrogenic confounds without layering in an aromatase inhibitor, boldenone offers a cleaner experimental model. The erythropoietic effects have been studied, and the compound has shown up as a comparator in androgen receptor binding assays. That’s real bench utility, if narrow. We think the reference-probe angle is the only serious argument for keeping it in a research inventory.

The evidence base is a genuine problem. Most of what exists is pharmacokinetic characterization covering ester hydrolysis rates and detection windows for anti-doping work, plus veterinary pharmacology. Human clinical data is essentially observational, drawn from illicit use contexts rather than controlled trials. Replication across independent research groups for any specific effect claim is limited. Dont have the multi-lab, methodologically sound preclinical base you’d want before calling something a serious target.

Honestly, the main reason boldenone appears in a library like this is category completeness and its historical role as a reference AAS. For an investigator studying reduced-aromatization androgen biology, there are more accessible and better-characterized options: testosterone plus a well-characterized aromatase inhibitor gives more experimental control, and nandrolone carries actual clinical literature. We’d deprioritize boldenone for almost any active research program. The narrow reference-probe case keeps it off the floor, but old mechanism, thin controlled evidence, Schedule III friction, and a stagnant pipeline put it well down the priority list.

Novelty

18

Mechanism promise

20

In-category differentiation

25

Evidence quality

22

Translational signal

28

Research bench value

38

Rationale Boldenone scores low across novelty and mechanism because it’s a 75-year-old AR agonist variant with no active clinical program and a saturated-class mechanism; bench value is slightly elevated for its narrow use as a low-aromatizing reference probe, but the combination of thin controlled evidence and stagnant literature keeps the overall well below the Schedule III cap of 75.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Testosterone analog (1-dehydro testosterone)

A 1-dehydro testosterone analog; an injectable AAS originally developed for veterinary use, widely diverted to human non-medical use.

Abstract

Boldenone (17-beta-hydroxyandrosta-1,4-dien-3-one; CAS 846-48-0; molecular formula C19H26O2; molecular weight 286.41) is a 1-dehydro testosterone analog originally developed at Ciba and approved by the FDA in 1949 (Parenabol, withdrawn) and subsequently developed for veterinary use as Equipoise (the brand most associated with the compound). The 1,2 double bond reduces aromatase substrate quality, producing approximately 50 percent the estrogen conversion of testosterone at equivalent doses; this is the principal pharmacological feature distinguishing boldenone from testosterone. The undecylenate ester (Equipoise) provides a long half-life (approximately 14 days) for veterinary or non-medical injectable use. Schedule III in the US (covered by the AAS Control Act despite no human medical approval). Plasma half-life of native boldenone is short; ester formulations release over weeks. Used as a reference low-aromatizing testosterone analog in research.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-391Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Trenbolone

Plain-language summaryIntrigue 55 / 100

Trenbolone is a 19-nortestosterone derivative with an extra 11-dehydro double bond, originally approved as a cattle growth implant (Finaplix). It is one of the most potent anabolic steroids ever made: it binds the androgen receptor with affinity comparable to testosterone but with greater intrinsic activity, the 19-nor structure prevents aromatization to estrogen, and the 11-dehydro modification blocks the 5-alpha-reduction step that normally limits AR engagement. The combination produces dramatic anabolic effects paired with an unusually rough side-effect profile: paradoxical gynecomastia (via progesterone receptor activation), drenching night sweats, insomnia, anxiety, and putative kidney stress. Schedule III. Used as the canonical high-potency AAS reference in research. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundResearch workhorse

37/100

High-potency AAS reference probe with mature pharmacology and no active clinical development story

Look, trenbolone is one of those compounds where the chemistry is genuinely interesting and the research utility is real, but you have to be honest about what era of research this thing lives in. The 19-nor scaffold, the 11-dehydro double bond that blocks 5-alpha-reduction, the preserved aromatization resistance, the high AR affinity (Ki around 0.5 nM with strong intrinsic activity) plus meaningful progesterone receptor engagement. Structurally, thats a sophisticated profile. The paradoxical gynecomastia pathway via PR rather than via estrogen conversion is actually one of the more pharmacologically interesting features of the compound, and its been a useful case study in how non-genomic and receptor-crosstalk effects complicate the simple androgen narrative.

But the literature on trenbolone is mature in the worst way for this rubric. The bulk of it is veterinary (Finaplix cattle implant, growth promotion endpoints), forensic (WADA metabolite mapping, urine detection windows), or abuse-monitoring (adverse effect cataloguing from non-medical human use). There is no active clinical development program. Nobody is running a phase 1. The safety signal, the pharmacokinetics across the acetate and enanthate ester forms, the receptor binding constants. these are known quantities. You are not going to discover something new about trenbolone’s mechanism in 2026 that hasn’t already been characterized.

Where we think it earns its place in the library is specifically as a reference AAS for bench work. If your program involves AR pharmacology, comparing intrinsic activity hierarchies across the AAS class, or dissecting how progestogenic activity in an AAS modulates downstream androgenic signaling, trenbolone is the correct tool for the potency ceiling end of that comparison set. The structural constraints are actually useful in controlled assays because you eliminate the confounds from aromatization and 5-alpha-reduction pathways that complicate testosterone-based experiments. That probe value is real and specific.

What we don’t like: no human therapeutic signal, no active mechanistic frontier, Schedule III access hurdles in the US, and a research conversation thats largely closed rather than opening. The translational story runs in one direction. cattle and forensic labs. For a bench scientist building a new program in 2026, this isn’t where you start. For a scientist who needs a high-affinity AR/PR reference compound with well-defined pharmacokinetics to anchor a comparison study, it’s genuinely useful. That’s the honest framing and it produces a score in the high 30s, not something higher.

Novelty

20

Mechanism promise

30

In-category differentiation

45

Evidence quality

50

Translational signal

35

Research bench value

55

Rationale Trenbolone scores low on novelty and translational signal because the compound is decades old, the pharmacology is exhaustively characterized, and the human-relevant literature is almost entirely forensic or abuse-monitoring in nature. Bench value rescues it modestly as a high-affinity reference AAS for AR/PR crosstalk studies, but the Schedule III cap never binds because the calculated score sits comfortably below 75.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

19-nor 11-dehydro AAS (high-potency)

A 19-nortestosterone-derived 11-dehydro AAS; one of the most potent AAS used in cattle (Finaplix) and diverted to non-medical use.

Abstract

Trenbolone (17-beta-hydroxyestra-4,9,11-trien-3-one; CAS 10161-33-8; molecular formula C18H22O2; molecular weight 270.37) is a 19-nortestosterone-derived 11-dehydro AAS approved for veterinary use as growth-promoting cattle implant (Finaplix). The compound is among the highest-potency AAS at the androgen receptor (Ki approximately 0.5 nM, comparable to testosterone with greater intrinsic activity); the 19-nor structure prevents aromatization to estrogen, and the 11-dehydro double bond prevents 5-alpha-reduction to a more potent metabolite (the AR-active form is trenbolone itself). The AR potency combined with progesterone receptor activity produces pronounced anabolic effects with significant adverse profile: gynecomastia (paradoxical, via progestogenic activity), dramatic sweating, sleep disturbance, anxiety, and putative kidney stress. Plasma half-life of native trenbolone is short (hours); the acetate, enanthate, and hexahydrobenzylcarbonate ester forms used non-medically range from days to weeks. Schedule III in the US. Used as a high-potency reference AAS in research.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-392Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Beta-Hydroxybutyrate (BHB)

Our opinion on this compoundEstablished, active research

49/100

Endogenous ketone with a real HDAC story, but novelty ceiling is low for a metabolite your liver makes daily

Look, BHB is one of those compounds where the question isn’t whether it does something interesting, it’s whether you’re actually learning anything new by studying it. Your liver produces it whenever you fast past 12 hours. That basic fact puts a ceiling on how exciting the molecule can be as a research object, no matter how elegant the downstream biology turns out to be.

And the downstream biology is genuinely more interesting than the fuel-substrate story suggests. The Shimazu group’s 2013 Cell paper showing BHB inhibits class I HDACs (specifically HDAC1, 2, and 3) at low millimolar concentrations changed how serious metabolic researchers think about fasting. That’s not a trivial mechanism. HDAC inhibition drives FOXO3a activation and upregulates oxidative stress resistance genes, which connects the ketogenic state to longevity biology in a way thats not just hand-waving. The GPR109A agonism adds another layer: this receptor mediates anti-lipolytic and anti-inflammatory effects in adipose and immune tissue, and it’s the same target that makes niacin interesting at the vascular level. Multi-target, real signal.

The problem is the evidence base is scattered across too many indications to cohere into a single compelling research story. Exercise performance data from the Clarke and Holdsworth labs using ketone esters is among the cleanest human data we have on exogenous ketones, but effect sizes in trained athletes are modest and context-dependent. The Alzheimer and cognitive work is built mostly on the AC-1202/Axona medium-chain triglyceride history and more recent ketone ester pilot studies: directionally interesting, replication incomplete. The longevity angle via mTOR modulation and autophagy induction is predominantly preclinical, and isolating BHB’s contribution from the broader fasting context is methodologically hard.

What we actually like about BHB for bench work is the HDAC angle used as an epigenetic tool. If you want to model class I HDAC inhibition in a physiologically relevant way, exogenous BHB gives you a probe that your cell already recognizes. That has real value in metabolic and neuroepigenetics research that synthetic HDAC inhibitors with off-target profiles don’t fully replicate. The ketone monoester formulation (Delta G, formerly HVMN Ketone) is the format serious exercise physiology labs have standardized on for controlled BHB elevation; BHB salts are cheaper but raise plasma osmolality in ways that confound interpretation.

The overall picture: a compound worth having in a metabolic or longevity research program, with a mechanism story that holds up, but not something that would make a serious investigator rearrange their priorities. The HDAC and GPR109A angles keep it above the metabolite baseline; the endogenous ceiling keeps it from competing with genuinely novel research compounds.

Novelty

30

Mechanism promise

55

In-category differentiation

45

Evidence quality

58

Translational signal

50

Research bench value

65

Rationale BHB escapes the foundational-metabolite cap because the HDAC class I inhibitor discovery (Shimazu et al., 2013) and GPR109A signaling angle constitute a genuinely mechanistically interesting layer beyond simple fuel supplementation, analogous to how Mg-threonate escapes the basic-mineral cap. Scored as established-active: solid multi-mechanism biology, decent clinical evidence in exercise and some cognitive work, but novelty is inherently constrained because this is an endogenous molecule produced by normal hepatic metabolism.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Endogenous ketone body / signaling metabolite

Beta-hydroxybutyric acid; the principal endogenous ketone body; a metabolic fuel and HDAC inhibitor with cognitive and longevity research interest.

Abstract

Beta-hydroxybutyrate (BHB, (R)-3-hydroxybutyric acid; CAS 625-72-9; molecular formula C4H8O3; molecular weight 104.10) is the principal endogenous ketone body, produced by hepatic mitochondrial beta-oxidation of fatty acids during fasting, ketogenic dieting, prolonged exercise, or insulin deficiency. The compound serves multiple roles: as a metabolic fuel substrate for brain, heart, and skeletal muscle (oxidized via beta-hydroxybutyrate dehydrogenase to acetoacetate, then to acetyl-CoA for TCA cycle entry); as an endogenous HDAC inhibitor (specifically class I HDACs at low millimolar concentrations); and as a ligand at hydroxycarboxylic acid receptor 2 (HCA2/GPR109A). Approved clinical use is the historical ketogenic diet for refractory pediatric epilepsy. Research interest spans neurodegenerative disease (Alzheimer, Parkinson), cognition, longevity (mTOR/autophagy modulation), and exercise performance (ketone supplementation in endurance sport). BHB salts (Ca, Na, Mg, K salts) and esters (1,3-butanediol esters of BHB) are sold as ergogenic supplements; the ketone monoester (HVMN Ketone, Delta G) is the most thoroughly studied. Plasma half-life of exogenous BHB is approximately 1 to 3 hours depending on formulation. Used as the canonical ketone body in metabolic and longevity research.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-400Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
HMB (β-Hydroxy-β-methylbutyrate)

Our opinion on this compoundEstablished workhorse

37/100

Mature anti-catabolic metabolite with real catabolic-state signal but low novelty as a research target

Look, HMB has been around since the early 1990s, and the core story hasn’t changed much. It’s a metabolite of leucine, produced via alpha-ketoisocaproate during roughly 5% of leucine catabolism, and the proposed mechanism is straightforward: reduce protein breakdown through ubiquitin-proteasome pathway inhibition while nudging mTOR signaling upward. Thats a real mechanism. Just not a particularly exciting one. We’ve known how the proteasome works for decades, and HMB’s interaction with it is well-characterized to the point of being textbook.

The evidence picture is better than you’d expect from something marketed this aggressively. In catabolic states, the signal is genuine. HIV wasting trials, cancer cachexia cohorts, bedrest-induced atrophy protocols, and post-surgical recovery studies all show meaningful lean mass preservation at 3 g/day. The Vukovich group, Flakoll et al., and several independent labs replicated this in sarcopenic and hospitalized populations. That is the compound at its best. In healthy resistance-trained athletes, the effect size compresses fast. The meta-analyses in athletic populations are messy, and the dramatic early claims from Wilson et al. didn’t survive independent replication at scale.

The free acid form (HMB-FA) has better pharmacokinetics than the calcium salt, faster absorption and higher peak plasma concentration. Interesting story in theory. But most of the foundational clinical work used Ca-HMB, so the HMB-FA literature is thinner, and the practical effect-size advantage looks modest when you read the head-to-head data carefully. Not a reason to deprioritize the compound, but not a reason to get excited either.

What we don’t like about HMB as a research target: the mechanism doesn’t point at anything that isn’t already well-mapped. If you’re trying to understand proteasome biology, you’re reaching for more specific chemical probes. If you’re trying to build an anti-catabolic protocol, you’re comparing HMB to leucine supplementation, essential amino acid formulations, and the newer mitochondrial peptide work, and HMB doesn’t come out ahead on bench utility. The probe value is real but narrow. It works best as a comparator arm in muscle-wasting trial design. That’s about its ceiling.

For investigators in catabolic biology, it earns a place as a reference compound: well-sourced, defined pharmacokinetics, clean mechanism. For anyone focused on the frontier of muscle-sparing or anti-aging research, the interesting signals are coming from myostatin pathway modulators, mitochondrial peptides, and GLP-1 adjacent compounds. HMB is the baseline you measure against, not the signal you’re chasing. Honest assessment: score this one and move on.

Novelty

22

Mechanism promise

28

In-category differentiation

35

Evidence quality

52

Translational signal

52

Research bench value

40

Rationale HMB lands just under the foundational-metabolite ceiling on its own calculated merit: the catabolic-state evidence base is genuine and multi-lab replicated, but the mechanism is unremarkable, novelty is low, and differentiation from leucine itself or EAA protocols is modest. No cap binds because the axes score it there naturally.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Leucine metabolite (anti-catabolic supplement)

Beta-hydroxy-beta-methylbutyrate; a leucine metabolite that reduces muscle protein breakdown; used in catabolic states and as a supplement.

Abstract

HMB (beta-hydroxy-beta-methylbutyric acid; CAS 625-08-1; molecular formula C5H10O3; molecular weight 118.13; Ca-HMB salt CAS 135236-72-5) is a metabolite of the branched-chain amino acid leucine, produced by approximately 5 percent of leucine catabolism via alpha-ketoisocaproate. Mechanism: HMB reduces muscle protein breakdown via inhibition of the ubiquitin-proteasome pathway and enhanced cell membrane integrity; secondary effects on muscle protein synthesis through mTOR pathway activation. The clinical evidence is strongest in catabolic states (HIV wasting, cancer cachexia, sarcopenia of aging, bedrest, post-surgical recovery) where 3 g/day reduces protein breakdown and preserves lean mass. In healthy resistance-trained athletes, the effect is small. The free acid form (HMB-FA) has improved pharmacokinetics over the calcium salt (Ca-HMB) but most research uses Ca-HMB. Plasma half-life is approximately 2 hours. Used as a reference anti-catabolic supplement.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-399Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
L-Glutamine

Plain-language summaryIntrigue 38 / 100

L-glutamine is the most abundant free amino acid in human plasma, serving as a fuel substrate for gut lining cells and immune cells and as an ammonia transport carrier. Clinical evidence is solid in critical illness contexts (severe burns, sepsis, post-surgical recovery), where parenteral or enteral glutamine improves nitrogen balance and may reduce infection rates. The popular supplement use in healthy athletes for recovery and immune support, however, has very thin supporting evidence: most oral glutamine is extracted by the gut on first pass and never reaches systemic circulation. Reference amino acid in immunometabolism and clinical nutrition research, but generally overhyped in the supplement context. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundBasic amino acid

28/100

Conditionally essential amino acid with solid critical-care history but minimal frontier research value

Look, glutamine is the most abundant free amino acid in human plasma, and that abundance tells you something important: this is basic cellular infrastructure, not frontier pharmacology. The compound has been characterized for decades. The biology is mature. The interesting questions about glutamine have largely been answered, and the field has moved on to more specific modulators of the pathways glutamine feeds into.

The mechanism is real and worth understanding. Enterocytes and immune cells run on glutamine during catabolic stress states, and in the ICU context, burns, sepsis, post-surgical recovery, parenteral and enteral glutamine supplementation has demonstrated genuine benefit. Nitrogen balance improvements and reduced infection rates have been replicated across multiple centers. Thats legitimate evidence, and we give it credit here. The problem is what happens when you move outside the critical care ward.

Oral supplementation in healthy or recreationally active individuals is a fundamentally different situation. The gut extracts the vast majority before it reaches systemic circulation. Plasma half-life is about an hour. Claims around athlete recovery, gut permeability, and immune support in healthy populations have not held up well under controlled conditions. The supplement market ran well ahead of the evidence and stayed there. We dont find this surprising given the pharmacokinetics.

As a research tool, glutamine has a narrow supporting role. It functions as a reference amino acid in immunometabolism work, useful for establishing nitrogen flux baselines, tracking amino acid transfer via metabolic tracers, and studying enterocyte energy dependence. But thats a background role in someone else’s experiment. The more interesting action in amino acid signaling right now sits with SLC1A5/ASCT2 modulators, glutaminase inhibitors in oncology (CB-839 and related compounds), and the intersection of glutamine sensing and mTOR complex activation. Those are the derivative questions worth pursuing; glutamine itself is the substrate, not the lever.

The one area we’d monitor is the critical-illness subpopulation question. There’s ongoing effort to define which patients actually benefit and at what illness stage, including revisiting the mixed results from the REDOX and SUGARMILL trials. That’s clinical nutrition work with real stakes. But it’s not exploratory pharmacology and it doesn’t change what glutamine is as a research object.

For the library, glutamine earns its place as reference context. It’s part of the vocabulary. It’s not an investigation target for a serious bench program right now.

Novelty

10

Mechanism promise

18

In-category differentiation

18

Evidence quality

52

Translational signal

48

Research bench value

38

Rationale Raw calculation lands at 28, already below the 32 basic-aa cap, so the cap does not further limit the score. Novelty and differentiation drag the total down hard; evidence gets partial credit for replicated critical-care trials, but bench value is narrow and translational signal evaporates outside the ICU context.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Conditionally essential amino acid (immunometabolic substrate)

L-glutamine; the most abundant free amino acid in plasma; a substrate for enterocyte and immune cell metabolism and a popular but evidence-limited supplement.

Abstract

L-glutamine ((S)-2,5-diamino-5-oxopentanoic acid; CAS 56-85-9; molecular formula C5H10N2O3; molecular weight 146.14) is a conditionally essential alpha-amino acid that is the most abundant free amino acid in human plasma (approximately 500 to 800 micromolar). Glutamine is biosynthesized from glutamate and ammonia by glutamine synthetase, with skeletal muscle and lung as principal source tissues. The compound serves as a substrate for enterocyte and immune cell metabolism (the principal biological role outside protein synthesis) and as an ammonia transport carrier. Clinical use is well-established in critical illness (burn injury, sepsis, post-surgery) where parenteral or enteral glutamine improves nitrogen balance and may reduce infection rates; the supplement use in healthy athletes for recovery and immune support has limited supporting evidence. Plasma half-life is approximately 1 hour; the gut largely extracts oral glutamine, with minimal systemic delivery. Used as a reference amino acid in immunometabolism and clinical nutrition research.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-398Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
L-Arginine

Plain-language summaryIntrigue 40 / 100

L-arginine is a conditionally essential amino acid that serves as the direct substrate for nitric oxide synthase (the enzyme that builds NO) and as a urea cycle intermediate for ammonia clearance. Despite being the literal substrate, oral arginine is a surprisingly poor way to raise nitric oxide because intestinal and liver arginase chew through most of it before it reaches systemic circulation. Citrulline, which bypasses arginase by converting to arginine in the kidney, is paradoxically more effective at raising plasma arginine. Cardiovascular research has tested arginine for endothelial dysfunction, peripheral artery disease, and erectile dysfunction with mixed and underwhelming results. Reference NOS substrate amino acid in research, more useful as a comparator than a therapy. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundBasic amino acid

27/100

The canonical NOS substrate amino acid, outperformed by citrulline and consistently underwhelming in clinical trials

Look, L-arginine is one of those compounds that looks interesting on paper and disappoints on delivery. It’s been a research subject since the 1980s, it’s the canonical NOS substrate in every biochemistry textbook, and it’s generated hundreds of clinical trials. None of that makes it a compelling research target in 2026.

The mechanism is real: L-arginine is the direct substrate for all three nitric oxide synthase isoforms, producing NO and citrulline. The urea cycle role is equally well-characterized. The problem is what actually happens when you administer it orally. Intestinal and hepatic arginase get to it first, converting arginine to ornithine before it reaches systemic circulation. So the compound that is literally defined by being the NOS substrate is, ironically, poor at delivering to NOS via the oral route. L-citrulline bypasses arginase through renal conversion to arginine and is paradoxically more effective at raising plasma arginine levels. Thats a hard pharmacokinetic ceiling to work around, and it cuts to the core of why this compound doesnt hold up as a serious research priority.

The clinical literature reflects this. Endothelial dysfunction, peripheral artery disease, erectile dysfunction, heart failure: L-arginine has been investigated across all of them, and the results are consistently mixed-to-modest. The 2006 WISE trial extension published in JAMA had to be stopped early after supplementation showed no benefit in coronary heart disease patients and produced a signal toward increased post-MI mortality in older subjects. Meta-analyses that followed showed results highly dependent on baseline NO status and population. This isn’t a compound where the evidence is immature and promising; it’s a compound where the evidence is mature and unimpressive. That’s a meaningful distinction when you’re deciding where to put bench time.

As a research tool, L-arginine does retain some narrow utility. It’s the reference substrate for NOS biology, and investigators studying arginase competition, urea cycle disorders, or iNOS induction models use it as a standard. But it’s not indispensable the way rapamycin is for mTOR work. Any lab seriously interested in NO biology will reach for more selective tools, or just use citrulline loading to model systemic arginine availability.

We dont see a strong case for prioritizing L-arginine as a research target. The mechanism is saturated, the evidence base is mature and mixed, and the compound is actively outperformed by its metabolic precursor in its own primary application. It earns a reference role in urea cycle and canonical NOS substrate work, but thats a narrow lane. Investigators with finite resources have better options in almost every direction this compound points.

Novelty

10

Mechanism promise

20

In-category differentiation

15

Evidence quality

60

Translational signal

35

Research bench value

40

Rationale L-arginine scores low on novelty and differentiation because it’s a decades-old compound where citrulline strictly dominates its primary application via arginase bypass; evidence quality is decent for a basic amino acid but the translational signal is mixed-to-negative across cardiovascular endpoints, and bench value is narrow reference use only in NOS and urea cycle work. Calculated overall of 27 falls below the basic-aa cap of 32, so cap does not bind.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Conditionally essential amino acid / nitric oxide precursor

L-arginine; the direct substrate for nitric oxide synthase and a urea cycle intermediate; used as a pre-workout supplement and in cardiovascular research.

Abstract

L-arginine ((S)-2-amino-5-guanidinopentanoic acid; CAS 74-79-3; molecular formula C6H14N4O2; molecular weight 174.20) is a conditionally essential alpha-amino acid that serves as the direct substrate for nitric oxide synthase (NOS), producing NO and citrulline; arginine is also the rate-limiting urea cycle intermediate for ammonia clearance. Despite the direct NOS substrate role, oral arginine supplementation has limited efficacy at increasing systemic NO production because intestinal and hepatic arginase metabolizes arginine to ornithine before it reaches systemic circulation; citrulline, which is converted to arginine in the kidney bypassing arginase, is paradoxically more effective at raising plasma arginine. Clinical research has investigated arginine for cardiovascular conditions (endothelial dysfunction, peripheral artery disease, erectile dysfunction) with mixed results. Plasma half-life is approximately 1 to 2 hours. Used as the canonical NOS substrate amino acid in research.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-397Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Citrulline Malate

Plain-language summaryIntrigue 55 / 100

Citrulline malate combines L-citrulline (an amino acid your kidneys convert into L-arginine) with malic acid (a TCA cycle intermediate). The trick is that citrulline supplementation actually raises blood arginine more effectively than arginine itself, because it bypasses the intestinal arginase enzyme that destroys most oral arginine before it reaches circulation. Higher arginine fuels nitric oxide synthesis (vasodilation, the famous pre-workout pump) and supports urea cycle ammonia clearance. The malate component helps keep TCA-driven ATP production running. Standard pre-workout dosing is 6 to 10 g taken 60 to 90 minutes before exercise, with reasonable evidence for increased resistance training volume and reduced post-workout soreness. Among the more credible pre-workout ingredients. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

33/100

Well-understood pre-workout ingredient with solid exercise evidence but zero research novelty

Look, citrulline malate is one of those compounds where the science is basically done. The mechanism is completely mapped: L-citrulline converts to L-arginine in the kidneys, bypassing intestinal arginase, which degrades oral arginine before it reaches systemic circulation. That salvaged arginine then feeds nitric oxide synthase, driving vasodilation. The malate portion is a TCA cycle intermediate that supports aerobic ATP production and likely buffers ammonia accumulation during high-intensity work. Clean mechanism, understood for over two decades, nothing surprising here.

The evidence base is actually solid by supplement standards. Multiple RCTs have confirmed effects on resistance training volume, and there’s reasonably consistent data on reduced post-exercise muscle soreness across independent labs. The Perez-Guisado work and subsequent replications are well-documented in exercise physiology. We’re not talking about single-lab work or marketing claims dressed as research. The human translational signal is real and repeatable.

What kills the score is that none of this is interesting anymore. A bench scientist in 2026 is not reaching for citrulline malate as a research target. The NO pathway is saturated territory. The urea cycle angle has been thoroughly mapped. There is no novel indication space, no unexplored mechanism, no surprising biology to chase. The malate contribution specifically is contested: it’s not clear how much malic acid at standard pre-workout doses actually shifts TCA flux in exercising muscle, and the literature hasn’t convincingly resolved whether the 2:1 complex outperforms plain L-citrulline in any meaningful way. Nobody is writing grants to find out.

As a research tool, citrulline malate has essentially no probe value. If you want to study NO biology, you’d reach for L-NAME or well-characterized NOS inhibitors. If you want urea cycle work, there are purpose-built tools. The compound’s entire identity is pre-workout ingredient, and thats not what serious investigators are doing bench work on.

Differentiation is a problem too. The case for citrulline malate over plain L-citrulline rests primarily on industry framing. The malate may contribute something, but evidence that the specific complex has a scientifically meaningful edge over the amino acid alone is thin. You’re stacking two understood, unremarkable metabolites and hoping the combination exceeds the sum.

Honest assessment: this belongs in a sports nutrition product. We stock it because the exercise science is clean and it has utility in protocols where NO pathway manipulation is needed as a straightforward control condition. But it shouldn’t occupy any serious investigator’s attention in 2026.

Novelty

16

Mechanism promise

28

In-category differentiation

25

Evidence quality

58

Translational signal

55

Research bench value

22

Rationale Both L-citrulline and malic acid are fully characterized molecules with mapped pharmacology; the combination has decent RCT support for exercise performance but no novel mechanism, unexplored indication space, or meaningful bench utility to recommend it as a priority research target in 2026.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Amino acid + organic acid (NO precursor / TCA cycle support)

L-citrulline complexed with malic acid; a nitric oxide precursor (via arginine) and TCA cycle substrate used in pre-workout supplements.

Abstract

Citrulline malate (L-citrulline DL-malate, CAS 70796-17-7; complex of L-citrulline (CAS 372-75-8, C6H13N3O3, MW 175.19) and malic acid (CAS 6915-15-7, C4H6O5, MW 134.09); commercial 2:1 or 1:1 ratios) is a complex of the amino acid L-citrulline with malic acid. L-citrulline is converted in the kidneys to L-arginine, the substrate for nitric oxide synthase; circulating arginine produced from citrulline supplementation is paradoxically more effective than direct arginine supplementation owing to the bypass of intestinal arginase. The malic acid portion is a TCA cycle intermediate supporting aerobic ATP production. Combined, the compound improves exercise performance through vasodilation (nitric oxide-mediated), reduced ammonia accumulation (urea cycle support), and ATP production. Plasma half-life of citrulline is approximately 1 hour. Used widely in pre-workout supplements (8 to 10 g doses, 60 to 90 minutes pre-exercise) with documented effects on resistance training volume and reduced post-exercise soreness.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-396Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Beta-Alanine

Plain-language summaryIntrigue 60 / 100

Beta-alanine is a non-protein amino acid that serves as the rate-limiting ingredient for muscle carnosine synthesis. Supplementing for four to twelve weeks raises muscle carnosine by 30 to 80 percent, which improves the muscle’s ability to buffer the acid build-up that limits high-intensity exercise. The ergogenic benefit is most reliable for efforts lasting one to four minutes (where lactate buffering is the bottleneck), with meta-analyses showing about 2 to 3 percent improvement. The signature side effect is paresthesia, the harmless but distinct tingling sensation in the face and limbs, attributed to peripheral nerve activation by free beta-alanine. Sustained-release formulations and split dosing reduce the tingle. The relevant pharmacokinetic compartment is muscle carnosine, not plasma. Reference lactate-buffering ergogenic in sport science. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundBasic amino acid

32/100

Mature ergogenic with solid replicated evidence but essentially no research frontier remaining

Cap applied basic-aa cap (max 32)

Look, the science on beta-alanine is basically done. Not in a dismissive way, but in the literal sense: the mechanism is understood, the effect is replicated across multiple labs and meta-analyses, the dose range is characterized, the practical limitations are well-mapped, and the indication space has been fully staked out. For sport science investigators running a specific protocol, thats useful. For researchers looking for an interesting frontier problem, its not.

The carnosine precursor story is real and mechanistically elegant. Beta-alanine loads skeletal muscle carnosine over 4 to 12 weeks by bypassing serum carnosinase, which destroys orally administered carnosine before it reaches tissue. Elevated carnosine then acts as an intracellular pH buffer during high-intensity efforts in the 1 to 4 minute window. Roger Harris’s group established this in the mid-2000s, and the literature since has mostly confirmed and refined it rather than extended it in genuinely new directions. Meta-analyses converge on roughly 2 to 3 percent improvement in that specific exercise window. The effect is real. The question just isn’t very exciting anymore.

What we like: beta-alanine is actually the only practical way to meaningfully load muscle carnosine at scale. Direct carnosine supplementation fails because serum carnosinase cleaves it before it reaches muscle. That gives beta-alanine a legitimate claim as the right tool for carnosine-biology experiments, and the differentiation within that narrow niche is real. Evidence quality is genuinely better than most compounds in this library. Translational signal is solid.

What we don’t like: the ceiling. The question being answered by carnosine loading is narrow and not extending into new biology. No serious lab in 2025 is building a discovery program around beta-alanine unless carnosine is the specific object of study. And even then its a limited probe for a limited question.

The paresthesia profile is probably the most pharmacologically interesting angle the compound has left. Free beta-alanine activates peripheral sensory neurons, likely via MRGPRD receptors, producing the characteristic facial and skin tingling. There’s real neuroscience in that mechanism. But it hasnt generated much productive downstream research, and the effect is mainly a nuisance variable that sustained-release formulations are designed to suppress.

Honestly, if you’re already doing sport physiology research on acid-base dynamics during high-intensity exercise, beta-alanine is already in your toolkit. If you’re asking whether this belongs at the frontier of a discovery-oriented research library, the answer is mostly no. The library should surface what’s next. Beta-alanine is, definitively, what was.

Novelty

22

Mechanism promise

28

In-category differentiation

42

Evidence quality

62

Translational signal

58

Research bench value

42

Rationale Beta-alanine is the canonical carnosine-loading probe with legitimate replicated sport-science evidence, but the mechanism is settled, the indication space is narrow and fully characterized, and novelty is near-floor; the basic-aa structural cap binds at 32 and accurately reflects the research-frontier value for a discovery-oriented library.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Beta-amino acid / carnosine precursor

A non-proteinogenic beta-amino acid; the rate-limiting precursor for muscle carnosine synthesis; an ergogenic supplement that buffers exercise-induced acidosis.

Abstract

Beta-alanine (3-aminopropanoic acid; CAS 107-95-9; molecular formula C3H7NO2; molecular weight 89.09) is a non-proteinogenic beta-amino acid produced endogenously by uracil and dihydrouracil degradation. The compound is the rate-limiting precursor for skeletal muscle carnosine (beta-alanyl-L-histidine) synthesis. Pharmacologically, supplementation over 4 to 12 weeks elevates muscle carnosine by approximately 30 to 80 percent, increasing the muscle’s intracellular pH-buffering capacity during high-intensity exercise. The ergogenic effect is most pronounced for exercise durations of 1 to 4 minutes (where lactate buffering is rate-limiting); meta-analyses show approximately 2 to 3 percent improvement in such efforts. The characteristic side effect is paresthesia (tingling, particularly on face and extremities) attributed to peripheral nerve activation by free beta-alanine; sustained-release formulations and split dosing reduce this. Plasma half-life is approximately 25 minutes; the relevant pharmacokinetic compartment is muscle carnosine, which has a much longer turnover. Used as the canonical lactate-buffering ergogenic in sport science.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-395Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Nandrolone

Plain-language summaryIntrigue 52 / 100

Nandrolone (19-nortestosterone) is the parent of an entire class of anabolic steroids defined by the missing 19-carbon. That single deletion does two useful things: it reduces aromatization to estrogen and it prevents 5-alpha-reduction from making a more potent metabolite. Instead, 5-alpha-reduction in skin and other tissues yields dihydronandrolone, which has lower AR affinity than the parent, so androgenic side effects are blunted. The decanoate ester (Deca-Durabolin) gives a 14-day half-life IM; phenylpropionate is faster (3 to 4 days). Approved for anemia of kidney disease and historically for osteoporosis. Schedule III. Heavy non-medical use in bodybuilding for lean mass and (anecdotally) joint support. Sexual dysfunction with prolonged use is attributed to progestogenic metabolites. Canonical 19-nor AAS. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

45/100

Canonical 19-nor AAS with real reference probe value but no research frontier left to explore

Look, the nandrolone story is genuinely elegant in places, just not in places that matter for a 2025 research agenda. First synthesized in the late 1950s, esterified into Deca-Durabolin by the early 1960s, approved for anemia of chronic kidney disease and historically for osteoporosis. The pharmacology has a neat mechanistic inversion at its core: 5-alpha-reduction of nandrolone produces dihydronandrolone, which carries lower AR affinity than the parent compound. Thats the opposite of the testosterone-to-DHT relationship. The result is tissue-selective anabolism, reduced androgenic expression in tissues dominated by 5-alpha-reductase activity, and a dissociation profile that made 19-nortestosterone derivatives attractive for clinical development in the first place.

But elegant and worked-out-decades-ago are the same thing here. The mechanistic picture is in every AAS pharmacology review going back to the 1970s. The approved-drug status gives nandrolone genuinely solid translational signal, multiple regulatory approvals, and a pharmacokinetic profile that’s been characterized across ester formulations (decanoate at roughly a 14-day half-life, phenylpropionate at 3 to 4 days). That’s a meaningful advantage when you need rigorous comparators or a well-characterized 19-nor AAS in an experimental design. It’s just not a signal pointing at anything new.

The progestogenic activity angle is the most underexplored piece of the puzzle. The so-called deca dick phenomenon, attributed to progestogenic metabolites suppressing the HPG axis and competing at androgen-sensitive circuits in sexual function, is a legitimate research question that hasn’t been fully characterized in clean mechanistic terms. If your program is studying the intersection of progestogenic and androgenic signaling in reproductive neuroendocrinology, nandrolone is the reference compound. There’s no substitute as a canonical 19-nor probe in that specific context.

Outside that niche, we think the bench case for nandrolone as a primary investigation target is weak. The active research community working on tissue-selective anabolism has largely migrated toward SARMs with better selectivity windows and cleaner receptor profiles. The GLP-1 and peptide fields have absorbed the metabolic-anabolic interest. Nandrolone is competing against a much richer pharmacological toolkit and losing on novelty at every turn.

What keeps it off the bottom of the library is exactly that reference utility. Approved drug, well-characterized PK, canonical class membership, real translational signal. If you need a 19-nor AAS in your experiment, this is the compound. Honestly, thats a real but narrow claim, and the score reflects it.

Novelty

18

Mechanism promise

40

In-category differentiation

40

Evidence quality

65

Translational signal

68

Research bench value

55

Rationale Schedule III cap (75) does not bind since the weighted score lands at 45 on its own merits. Nandrolone scores well on evidence and translational signal because it is an approved drug with decades of clinical data, but novelty is near-floor and the mechanism has been fully characterized for 40-plus years; the residual value is as a canonical reference compound for 19-nor AR pharmacology, not as a primary investigation target.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

19-nortestosterone (parent of nandrolone class)

19-nortestosterone; the parent compound of the nandrolone class of AAS; the decanoate ester is approved for anemia and osteoporosis.

Abstract

Nandrolone (17-beta-hydroxyestr-4-en-3-one; CAS 434-22-0; molecular formula C18H26O2; molecular weight 274.40) is the parent compound of the 19-nortestosterone (nandrolone) class of AAS; the 19-nor modification reduces aromatization to estrogen and prevents 5-alpha-reduction to a more potent metabolite. The compound itself binds AR with affinity approximately 5-fold higher than testosterone but with reduced effects in some tissues (5-alpha-reduction by 5-AR produces dihydronandrolone, which has lower AR affinity than nandrolone, in contrast to testosterone-DHT relationship; the result is reduced androgenic side effects). The decanoate ester (Deca-Durabolin) provides a 14-day half-life for IM administration; the phenylpropionate ester provides a shorter (3 to 4 day) half-life. Approved for anemia of chronic kidney disease and (historically) osteoporosis. Schedule III. Widely used in non-medical bodybuilding for lean mass gains and (anecdotally) joint support. The “deca dick” sexual dysfunction is attributed to the progestogenic activity of nandrolone metabolites. Used as the canonical 19-nor AAS in research.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-393Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Creatine Monohydrate

Plain-language summaryIntrigue 75 / 100

Creatine is a small organic acid your body builds from arginine, glycine, and methionine, and stores almost entirely in skeletal muscle as phosphocreatine. The phosphocreatine pool serves as a rapid phosphate donor that regenerates ATP during high-intensity exercise. Supplementation expands that pool by roughly 20 to 40 percent, which translates to consistent gains of 5 to 10 percent in strength and power output across hundreds of trials. It is the most thoroughly studied ergogenic supplement, with stronger evidence than essentially anything else in the sports nutrition aisle. Newer research has expanded into cognition, neurodegenerative disease, and depression on the theory that creatine kinase activity matters in the brain too. Loading at 20 g per day for five days saturates muscle as fast as 3 to 5 g per day over three to four weeks. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundResearch workhorse

38/100

The gold standard ergogenic reference compound, too settled to be a compelling research target

Cap applied Foundational metabolite (max 38)

Look, creatine monohydrate is genuinely excellent at what it does. The phosphocreatine-to-ATP pathway is one of the cleanest mechanisms in exercise physiology, and the evidence base is staggering: hundreds of replicated trials across decades, consistent 5 to 10 percent improvements in strength and power output, meaningful lean mass effects. If you’re doing sport science or exercise physiology, this is the reference standard. You build your protocols around it.

The problem is that none of that makes it an interesting research target right now. The mechanism was settled in the 1990s. The loading vs maintenance debate (20 g/day for 5 days versus 3-5 g/day sustained, same endpoint, different timeline) was resolved years ago. The sourcing landscape is essentially a commodity market, which is great for reliability and terrible for differentiation. When something this well-understood is this cheap and this consistent, it stops being a research frontier and becomes infrastructure.

The emerging cognitive angle is worth noting, and we dont want to dismiss it entirely. Creatine kinase activity in the CNS is real biology, and there are small trials suggesting some signal in traumatic brain injury populations and mild depression. Watanabe and colleagues published on cognitive effects in vegetarians, where baseline brain creatine is predictably lower, and the effect size there is actually interesting. But honest appraisal puts this at the “plausible mechanism, replication needed” stage. It’s not a reason to score the compound higher when the primary ergogenic story has been exhausted for three decades.

What keeps creatines bench value positive is its role as the canonical ergogenic comparator. If you’re testing anything in the energy substrate or high-intensity power output space, you’re measuring against creatine. It’s the reference standard the field uses to anchor effect sizes. That has real utility, but it’s the utility of a ruler, not a discovery.

The score here is intentional. Creatine monohydrate is one of the most effective and well-documented supplements in existence, and we mean that without irony. It scores 38 precisely because this rubric asks about research frontier value, not product quality. A compound that has been fully characterized, whose mechanism generates no new hypotheses, and whose clinical application is essentially saturated is not where a serious bench scientist should be directing attention in 2026. We’d recommend it without hesitation in a protocol stack. We wouldn’t fund a primary research program around it.

Novelty

12

Mechanism promise

18

In-category differentiation

45

Evidence quality

80

Translational signal

72

Research bench value

40

Rationale Creatine monohydrate scores well on evidence quality and translational signal but near-zero on novelty and mechanism, producing a raw calculated score of 42; the foundational metabolite hard cap brings this to 38. The compound is exhaustively characterized and functions as research infrastructure rather than a research frontier.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Endogenous metabolite / ergogenic supplement

A nitrogenous organic acid; the most thoroughly studied ergogenic supplement; phosphocreatine pool expansion supports rapid ATP regeneration during high-intensity exercise.

Abstract

Creatine monohydrate (N-(aminoiminomethyl)-N-methylglycine; CAS 6020-87-7; molecular formula C4H9N3O2 (anhydrous); molecular weight 131.13) is a nitrogenous organic acid biosynthesized in the liver and kidneys from arginine, glycine, and methionine and stored in skeletal muscle (95 percent of body creatine pool). Mechanism: phosphocreatine, the phosphorylated storage form, donates phosphate to ADP via creatine kinase to rapidly regenerate ATP during high-intensity exercise; supplementation expands the muscle phosphocreatine pool by approximately 20 to 40 percent, supporting longer high-intensity efforts. The most thoroughly studied ergogenic supplement, with hundreds of trials demonstrating consistent ~5 to 10 percent improvement in strength and power output and meaningful effects on lean body mass. Emerging interest in cognitive enhancement, neurodegenerative disease (creatine kinase activity in brain), and depression. The 5-day loading protocol (20 g/day) versus daily maintenance (3 to 5 g/day) produces equivalent muscle saturation with maintenance over 3 to 4 weeks. Plasma half-life is approximately 3 hours; muscle storage is the relevant pharmacokinetic measure. Used as the canonical ergogenic supplement in sport science and exercise physiology research.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-394Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026

←Previous Page

1 … 48 49 50 51 52 … 69

Bench-grade research compounds. Cited research. Verified COAs.

kodiac.bio

Explore

Shop
Monographs
Lab Results
About
Affiliate program
Affiliate handbook

Account

Cart
My account

Help

Compliance
Contact

Quarterly dispatch

New batches and new monographs only. Unsubscribe in one click.

Write to us from the contact page to join the list.

Kodiac biolabs sells research compounds for in vitro and in vivo investigative purposes only. Products are not for human or veterinary consumption. Not for medical, diagnostic, or therapeutic use. By using this site you confirm you are acquiring research compounds for research purposes only.

Kodiac biolabs is not affiliated with the U.S. Food and Drug Administration. Products are research reagents, have not been evaluated by the FDA, and are not intended to diagnose, treat, cure, or prevent any disease.

© 2026 Kodiac biolabs LLC. All rights reserved.